“In the US, the use of drugs for treating depression, anxiety, and insomnia spiked 21% between February 16th and March 15th, when the coronavirus was deemed a pandemic,” finds a new survey. MISSD wants to stress the importance of following FDA guidelines that state consumers should be carefully monitored and caregivers should watch for and report any unusual changes in behavior when starting, stopping or changing drug dosage or type.

See article at: https://www.businessinsider.com/fda-streamlines-digital-psychiatry-approval-process-2020-4